Anti-CPT2 Antibody, clone 1G7 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1G7 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects Carnitine palmitoyltransferase 2 (CPT2). It targets an epitope within 18 amino acids from the mitochondrial matrix domain within the N-terminal half

KLH-conjugated linear peptide corresponding to 18 amino acids from the mitochondrial matrix domain within the N-terminal half of human Carnitine palmitoyltransferase 2 (CPT2).

Quality Control Testing

Evaluated by Western Blotting in Rat liver tissue lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected CPT2 in Rat liver tissue lysate.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected CPT2 in lysates from HT-29 cells and Human liver and Rat liver tissues..

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CPT2 in Human kidney and Human liver tissue sections.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CPT2 in HT-29 and MCF-7 cells.

Affinity Binding Assay: A representative lot of this antibody bound CPT2 peptide with a KD of 4.1 x 10-8 in an affinity binding assay.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Carnitine O-palmitoyltransferase 2, mitochondrial (UniProt: P23786; also known as EC:2.3.1.21, Carnitine palmitoyltransferase II, CPT II) is encoded by the CPT2 (also known as CPT1) gene (Gene ID: 1376) in human. CPT2 is a mitochondrial inner membrane protein that is involved in the synthesis of acylcarnitines from accumulated acyl-CoA metabolites. It is synthesized with a transit peptide, which is subsequently cleaved off. It catalyzes the transfer of long- and medium-chain fatty acids from cytoplasm into mitochondria, where oxidation of fatty acids takes place. It reconverts acylcarnitines back into the respective acyl-CoA esters that can then undergo β-oxidation, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent β-oxidation. It displays higher activity with medium (C8-C12) and long-chain (C14-C18) acyl-CoA esters. Deficiency of CPT2 can result in the most common inherited disorder of long-chain fatty acid oxidation affecting skeletal muscle. Mutations in CPT2 gene can result in a lethal neonatal form, a severe infantile hepato-cardio-muscular form, or a rather mild myopathic form characterized by exercise-induced myalgia, weakness, and myoglobinuria. In CPT2 deficiency, long‐chain acylcarnitines are transported across the inner mitochondrial membrane but cannot be converted to their corresponding long‐chain acyl‐CoAs. They accumulate in the mitochondrial matrix and are transported out into plasma. These elevated levels may produce cardiac arrhythmias. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonal. (Ref.: Joshi, PR., and Zierz, S. (2020). Molecules. 25(8); 1784; Violante, S., et al. (2010). Biochim. Biophys. Acta. 1802(9); 728-732; Elpeleg, ON., et al. (2001). Am. J. Med. Genet. 102(2); 183-187).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.